Sequel Statement Regarding Dean Kamen

Sequel Med Tech is aware of recent DOJ disclosures involving one of its founders and board members, Dean Kamen. Sequel’s Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes. To ensure independence, the board will create a special committee to include a representative not currently on the board, to oversee this review. Dean has voluntarily recused himself from any oversight of the special committee. While undergoing this review, Sequel will remain focused on our commitment to deliver  twiist™ to the diabetes community.